Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 4 records in total 4
    records per page




    Clinical Characteristics and outcomes in HBV carriers TRANS with COVID-19 in WuHan, China: a retrospective cohort study

    Authors: Jingjing Lu; Mu Hu; Xia Zhou; Hui Zhu; Feilong Wang; Jianhao Huang; Zhongliang Guo; Qiang Li; Qi Yin; Zhifeng Yang

    doi:10.21203/rs.3.rs-42476/v1 Date: 2020-07-13 Source: ResearchSquare

    Background: Coronavirus 2019 (COVID-19) is a novel infectious disease MESHD that was first reported in Wuhan, China, but has spread to all parts of the world. At the same time, because China has millions of HBV carriers TRANS, HBV infection MESHD has become a major public health problem in China. In this study, we aim to describe the clinical features of HBV carriers TRANS (AsC) infected with COVID-19 and to assess the factors that may affect the outcome during disease progression MESHD.Methods: This retrospective cohort study included 72 patients diagnosed with COVID-19 in Wuhan Jinyintan Hospital. These patients were also diagnosed as HBV carriers TRANS. The epidemiological characteristics, demographic features, clinical manifestations, laboratory test, treatment, management and final outcome were collected and analyzed.Results: The median age TRANS of 72 patients is 58.5 years old, of which 55.56% (n=40) are male TRANS. 20 (30.56%) patients were severe cases and 50 (69.44%) were non-severe cases. Fever MESHD Fever HP is the most common symptom, followed by cough MESHD cough HP, chest tightness HP and sputum. Laboratory test results including hematologic, biochemical, infection MESHD and coagulation parameters and several indicators, such as Aspartate Aminotransferase (AST), Total Bilirubin (TBil), Direct Bilirubin (DBil), Indirect Bilirubin (IBil), γ-glutamyl Transferase (GGT) showed difference between their admission and discharge. The level of Prealbumin (PA) and Serum SERO Amyloid A (SAA) in the study showed a significant trend from high to low, which has statistical significance.Conclusions: The clinical features of HBV carriers TRANS with COVID-19 have obvious systemic symptoms, such as fever MESHD fever HP, cough MESHD cough HP, and chest tightness HP. Compared with liver function data on admission and discharge, SARS-CoV-2 does not directly activate the Hepatitis B MESHD Hepatitis HP virus, and the risk of liver cell damage of HBV carriers TRANS with COVID-19 does not increase. Both PA and SAA are sensitive indicators and can be used to evaluate the prognosis and outcome of these patients.

    Protective roles of flu infections MESHD and BCG vaccination in lowering Covid-19 mortality

    Authors: Sanmoy Pathak; Mohit Kumar Jolly; Dipankar Nandi

    doi:10.21203/rs.3.rs-33242/v1 Date: 2020-06-04 Source: ResearchSquare

    The recent Covid-19 pandemic has caused a great loss of lives as well as affected economies in several countries. The loss of Covid-19 deaths MESHD is far greater in some countries compared to others. This observation led us to perform epidemiological analysis using disease MESHD and vaccination data in the public domain with respect to measles MESHD, hepatitis B MESHD hepatitis HP virus, polio, tuberculosis MESHD and flu from twenty five countries across the globe. There is no correlation between Covid-19 incidences or deaths MESHD, as well as vaccination coverage, with respect to diseases MESHD such as measles MESHD, hepatitis B MESHD hepatitis HP virus and polio. However, countries with lower cases of tuberculosis MESHD and higher cases of flu have a significant correlation with respect to Covid-19 deaths MESHD. In fact, countries with high BCG vaccination coverage show a significant negative correlation with Covid-19 deaths MESHD. Surprisingly, countries such as the USA, Italy, France and Spain which have flu vaccination, but not BCG vaccination, show maximum number of Covid-19 deaths MESHD. It appears that high numbers of flu infections MESHD are protective and can decrease the number of Covid-19 deaths MESHD. Importantly, countries with high flu cases and BCG vaccination, such as India, Egypt, South Africa etc, show relatively lower Covid-19 deaths MESHD, reinforcing the protective roles of BCG vaccination. Notably, these general trends are statistically significant for Covid-19 deaths MESHD but not Covid-19 incidences. The implications of our results are discussed with respect to the roles of microbial infections in the respiratory tract MESHD infections in the respiratory tract HP, vaccinations and other factors in lowering Covid-19 deaths MESHD.

    Network theoretic analysis of JAK/STAT pathway and extrapolation to drugs and viruses including COVID-19

    Authors: Arindam Banerjee; Rudra Prosad Goswami; Moumita Chatterjee

    doi:10.21203/rs.3.rs-25845/v1 Date: 2020-04-28 Source: ResearchSquare

    Whenever some phenomenon can be represented as a graph or a network it seems pertinent to explore how much the mathematical properties of that network impact the phenomenon. In this study we explore the same philosophy in the context of immunology. Our objective was to assess the correlation of “size” (number of edges and minimum vertex cover) of the JAK/STAT network with treatment effect in rheumatoid arthritis MESHD rheumatoid arthritis HP (RA), phenotype of viral infection MESHD and effect of immunosuppressive agents on a system infected with the coronavirus. We extracted the JAK/STAT pathway from Kyoto Encyclopedia of Genes and Genomes (KEGG, hsa04630). The effects of the following drugs, and their combinations, commonly used in RA were tested: methotrexate, prednisolone, rituximab, tocilizumab, tofacitinib and baricitinib. Following viral systems were also tested for their ability to evade the JAK/STAT pathway: Measles MESHD, Influenza A, West Nile virus, Japanese B virus, Yellow Fever MESHD Fever HP virus, respiratory syncytial virus, Kaposi’s sarcoma MESHD sarcoma HP virus, Hepatitis B MESHD Hepatitis HP and C virus, cytomegalovirus, Hendra and Nipah virus and Coronavirus. Good correlation of edges and minimum vertex cover with clinical efficacy were observed (for edge, rho= -0.815, R2= 0.676, p=0.007, for vertex cover rho= -0.793, R2= 0.635, p=0.011). In the viral systems both edges and vertex cover were associated with acuteness of viral infections MESHD. In the JAK/STAT system already infected with coronavirus, maximum reduction in size was achieved with baricitinib. To conclude, algebraic and combinatorial invariant of a network may explain its biological behaviour. At least theoretically, baricitinib may be an attractive target for treatment of coronavirus infection MESHD.

    The Clinically Validated Viral Superinfection MESHD Therapy (SIT) Platform Technology May Mitigate Severe Cases of COVID-19 Infections MESHD

    Authors: Imre Kovesdi; Marc Van Ranst; Peter M. Chumakov; Volker Sandig; Tibor Bakacs

    id:10.20944/preprints202002.0147.v3 Date: 2020-03-20 Source: Preprints.org

    The transmission TRANS characteristic of COVID-19 is of similar magnitude to severe acute respiratory syndrome MESHD-related coronavirus (SARS-CoV) and the 1918 pandemic influenza. The virus is now in more than 100 countries and on nearly all continents. The World Health Organization (WHO) declared the COVID-19 outbreak a pandemic. There is no current evidence from random clinical trials (RCTs) to recommend any specific anti-COVID-19 treatment for patients with suspected or confirmed COVID-19 infection MESHD. In order to mitigate the impact of the COVID-19 outbreak, here we propose an innovative superinfection MESHD therapeutic (SIT) strategy, which could complement the development of prophylactic vaccines. SIT is based on clinical observations that unrelated viruses might interact in co-infected patients. During SIT, the patient benefit from superinfection MESHD with an apathogenic dsRNA virus such as the infectious bursal disease virus MESHD (IBDV), which is a powerful activator of the interferon-dependent antiviral gene program. An attenuated vaccine strain of IBDV was already successfully administered to resolve acute and persistent infections MESHD induced by two completely different viruses, the hepatitis B MESHD hepatitis HP (DNA) and C (RNA) viruses (HBV/HCV). Importantly, the epidemiological efficacy of a similar strategy to SIT had already been successfully tested in large controlled trials. Standard live orally administered enterovirus vaccines that stimulate the production of endogenous interferon of the host mitigated the seasonal outbreaks of influenza and other associated acute respiratory infections MESHD in 152,042 individuals without adverse reactions.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.